FDA Approves First Targeted Therapy for EGFR Lung Cancer with Exon 20 Mutations
Just a couple of months after receiving the FDA’s breakthrough therapy designation, Janssen’s Rybrevant has notched an accelerated approval. On May 21, the novel bispecific antibody was greenlit by the …
Read More